- Home
- RIGL vs MCS Comparison
RIGL vs MCS Comparison
Compare RIGL & MCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | MCS |
|---|---|---|
| Founded | 1996 | 1935 |
| Country | United States | United States |
| Employees | N/A | 8390 |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 541.6M |
| IPO Year | 2000 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RIGL | MCS |
|---|---|---|
| Price | $29.36 | $17.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $45.67 | $23.33 |
| AVG Volume (30 Days) | ★ 313.7K | 130.3K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.69% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 19.48 | 0.77 |
| Revenue | $294,282,000.00 | ★ $758,458,000.00 |
| Revenue This Year | N/A | $12.05 |
| Revenue Next Year | $12.75 | $3.15 |
| P/E Ratio | ★ $1.48 | $22.97 |
| Revenue Growth | ★ 64.15 | 3.11 |
| 52 Week Low | $16.88 | $12.85 |
| 52 Week High | $52.24 | $20.02 |
Technical Indicators
Market Signals| Indicator | RIGL | MCS |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 42.31 |
| Support Level | $28.08 | $14.66 |
| Resistance Level | $30.59 | $17.92 |
| Average True Range (ATR) | 1.13 | 0.63 |
| MACD | -0.22 | -0.23 |
| Stochastic Oscillator | 16.16 | 12.64 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.